Purpose: This analysis examines the impact of ustekinumab on overall health-related quality of life (HRQoL).
Introduction
Psoriasis is a chronic inflammatory skin disease affecting approximately 2-3% of the world's population. 1 The negative impact of psoriasis on health related quality of life (HRQoL) is considered comparable with that of other major systemic diseases. 2, 3 Interleukins-12 and -23 are cytokines that may elicit aberrant Th1 and Th17 immune responses and are considered possible therapeutic targets for psoriasis. Ustekinumab (CNTO 1275) is an IgG1 kappa monoclonal antibody to human IL12/23p40. PHOENIX 1 is a Phase 3 trial evaluating the safety and efficacy of ustekinumab for the treatment of moderate to severe psoriasis. To evaluate the impact of ustekinumab on HRQoL among patients with moderate to severe psoriasis, data from the PHOENIX 1 study were analyzed.
Study Design
PHOENIX 1 is a multicenter, randomized, double-blind, placebo-controlled study of ustekinumab in patients with moderate to severe plaque psoriasis Eligible patients were at least 18 years old, had a diagnosis of plaque psoriasis for at least 6 months, were candidates for phototherapy or systemic therapy, had a baseline PASI ≥12, and had ≥10% Overall health related quality of life was assessed using the Medical Outcomes Study Short-Form
(SF-36) with higher scores indicating better QoL
Skin disease-specific quality of life was assessed using the Dermatology Life Quality Index (DLQI) with lower scores indicating better QoL
Clinically meaningful improvement in HRQoL was defined as a change in score of ≥5 points in the DLQI, SF-36 Physical Component Score (PCS), or SF-36 Mental Component Score (MCS) 4, 5 Continuous variables were compared using an analysis of variance on the van der Waerden normal scores and binary endpoints were compared using Cochran-Mantel-Haenszel Statistics
Results
Baseline demographic and clinical characteristics were similar across treatment groups, with an SF-36 mean PCS score of 47.9, mean MCS score of 49.8, and mean DLQI score of 11.5 ( Significantly greater improvements from baseline in DLQI scores were observed in patients treated with ustekinumab 45mg (3.6) and 90mg (4.5) than patients in the placebo group (0.9) as early as 
Conclusions
Ustekinumab rapidly and significantly improves disease-specific quality of life, an improvement that is maintained over time Ustekinumab significantly improves multiple aspects of overall quality of life, including both physical and mental functioning
